SFM
BMRN icon

Sphera Funds Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sphera Funds Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-80,000
Closed -$7.4M – 110
2016
Q3 		$7.4M Buy
+80,000
New +$7.53M 1.21% 18
2015
Q3 		– Sell
-1,000
Closed -$13.7M – 129
2015
Q2 		$13.7M Buy
+1,000
New +$124K 1.34% 13

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sphera Funds Management's BMRN Position: Q2 2026 in Review

Sphera Funds Management increased its BioMarin Pharmaceuticals (BMRN) stake by 135% in Q2 2026, buying an estimated $10.3M and bringing the position to 328,550 shares worth $18.8M. The position accounts for 2.45% of the portfolio, ranked #9.

Sphera Funds Management first reported a position in BMRN in Q2 2014 and has held it in 20 quarters since. The position peaked at $21.3M in Q4 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sphera Funds Management held 328,550 shares of BioMarin Pharmaceuticals worth $18.8M as of Q2 2026.
  • Sphera Funds Management bought 188,650 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $10.3M.
  • BioMarin Pharmaceuticals made up 2.45% of Sphera Funds Management's portfolio in Q2 2026, its #9 holding.
  • Sphera Funds Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 20 quarters since.
  • Sphera Funds Management's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2019.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.